About
What it is and where it shows up.
Amla powder is the dried and ground fruit of Phyllanthus emblica L. (syn. Emblica officinalis Gaertn.), a tree native to India and Southeast Asia. It is used as a food ingredient, nutraceutical, and traditional Ayurvedic remedy, prized for its exceptionally high vitamin C content, polyphenols (ellagitannins, gallic acid, ellagic acid), and potent antioxidant properties.
Safety summary
The regulatory and scientific consensus.
Amla powder is generally safe and well-tolerated at typical dietary and supplemental doses (up to 500 mg/day confirmed in clinical trials); it carries no IARC carcinogenicity classification and no bans in major jurisdictions. Due to demonstrated antiplatelet and hypoglycemic activities, caution is warranted for individuals taking anticoagulants or antidiabetic drugs. Its high oxalate content may be a concern for individuals prone to calcium oxalate kidney stones.
Regulatory landscape
What food-safety regulators have decided.
| Jurisdiction | Status | Note |
|---|---|---|
| EFSA (European Food Safety Authority) (European Union) | Approved | Amla (Emblica officinalis) is permitted as a food ingredient in the EU. However, EFSA (2011) did not substantiate health claims related to LDL-cholesterol maintenance (ID 4041) or protection of DNA, proteins, and lipids from oxidative damage (ID 4042) under Regulation (EC) No 1924/2006. No E number or INS number assigned; no specific ADI established. Not listed in Novel Food Catalogue as restricted.source |
| FSSAI (Food Safety and Standards Authority of India) (India) | Approved | Amla fruit in minimally processed forms (dried or powdered) is classified as a regular food ingredient under FSSAI and is exempt from nutraceutical classification. It is also permitted as a botanical ingredient in health supplements and nutraceuticals under FSS (Health Supplements, Nutraceuticals, FSDU, FSMP, Functional Food and Novel Food) Regulations, 2016. Specific health benefit claims require prior approval from FSSAI.source |
| FDA (Food and Drug Administration) (United States) | Approved | Amla powder is widely sold in the US as a dietary supplement ingredient regulated under DSHEA (Dietary Supplement Health and Education Act, 1994). No formal FDA GRAS (Generally Recognized As Safe) self-affirmation or notice for amla powder as a conventional food additive has been publicly identified. Used as a food ingredient without specific approval requirements when consumed as whole/minimally processed fruit.source |
Who should approach with care
Whose guidance would steer them away.
Kidney Disease — Amla fruit is high in oxalates; excessive or supplemental consumption may increase the risk of calcium oxalate kidney stone formation in susceptible individuals.
Diabetes — Amla has demonstrated hypoglycemic activity in clinical and animal studies; concurrent use with antidiabetic medications may produce additive blood glucose-lowering effects requiring dose monitoring.
Heart Disease — Amla exhibits antiplatelet activity (reductions in von Willebrand factor and thrombin markers observed in RCT, PMC6926135), which may potentiate anticoagulants (e.g., warfarin) or antiplatelet drugs (e.g., aspirin) and increase bleeding risk.
Pregnancy — Insufficient clinical safety data exist for concentrated amla powder supplementation during pregnancy; use beyond normal culinary dietary amounts should be reviewed with a healthcare provider.
Infants — FSSAI nutraceutical regulations specify reduced permitted usage levels for young children, and concentrated amla powder supplementation is not established as safe for infants.
Research citations
The sources behind this verdict.
- 1PubMed. Functional and Nutraceutical Significance of Amla (Phyllanthus emblica L.): A Review, 2022. pubmed.ncbi.nlm.nih.gov
- 2FSSAI. Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016 – Compendium Version I (2021), 2021. fssai.gov.in
- 3PubMed. Clinical evaluation of Emblica Officinalis Gaertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study, 2019. pmc.ncbi.nlm.nih.gov
- 4PubMed. Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: a double-blind, randomized, placebo-controlled clinical trial, 2018. pubmed.ncbi.nlm.nih.gov
- 5EFSA. Scientific Opinion on the substantiation of health claims related to the raw fruit of Emblica officinalis Gaertn. and maintenance of normal blood LDL-cholesterol concentrations (ID 4041) and protection of DNA, proteins and lipids from oxidative damage (ID 4042) pursuant to Article 13(1) of Regulation (EC) No 1924/2006, 2011. efsa.europa.eu
Independently researched5 citations